Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Original Article from The New England Journal of Medicine — Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

  • Long-acting injectable cabotegravir (CAB-LA) given intramuscularly every 8 weeks was superior to daily oral TDF–FTC in preventing HIV infection among MSM and transgender women. Kudos for including transgender women in this study!